Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

·1 min read

GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.

Altimmune management will host a conference call and webcast with a slide presentation beginning at 8:30 am E.T. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at The company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Conference Call Information:


Tuesday, September 28


8:30 am Eastern Time

Domestic Dial-in:

(844) 615-6509

International Dial-in:

(918) 922-3148

Conference ID:



About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting